secwatch.observer — SEC 8-K summary
======================================

Issuer:     Eton Pharmaceuticals, Inc. (ETON)
CIK:        0001710340
Form:       8-K
Filed at:   2024-11-25T23:59:59+00:00
Accession:  0001437749-24-036095
Event type: m_and_a
Sentiment:  positive
Materiality: 0.65
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Eton Pharmaceuticals acquires U.S. rights to Amglidia (glyburide oral suspension) for neonatal diabetes
--------------------------------------------------------------------------------

- No upfront payment; up to $2.35M in milestone payments plus 14% royalty on net sales.
- Amglidia approved by EMA in 2018, has U.S. FDA Orphan Drug Designation.
- Targets neonatal diabetes, a rare condition affecting ~300 U.S. patients with no FDA-approved oral treatment.
- Eton plans FDA meeting in Q1 2025 and expects NDA submission in 2026.
- Eton can terminate within 30 days of FDA meeting minutes without milestone liability.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1710340/000143774924036095/0001437749-24-036095-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1710340/000143774924036095/eton20241117_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-036095

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer